How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

597 results for

Melasma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Topical 3% tranexamic acid enhances the efficacy of 1064-nm Q-switched neodymium-doped yttrium aluminum garnet laser in the treatment of melasma. (PubMed)

Topical 3% tranexamic acid enhances the efficacy of 1064-nm Q-switched neodymium-doped yttrium aluminum garnet laser in the treatment of melasma. A QS-NdYAG laser (QSNYL) and topical tranexamic acid (TA) have been widely used. However, no study has yet reported the efficacy of using both QSNYL and TA as a combined treatment for melasma.To evaluate the efficacy and adverse effects of topical 3% TA combined with 1064-nm QSNYL as a treatment for melasma.A randomized, prospective, split-face (...) treatment (p < 0.05), while no significant changes were observed in the laser-alone treatment. More than 80% of the participants noticed a >50% improvement on the side with combination therapy at every follow-up visit. No serious adverse events were reported.Topical TA as an adjuvant demonstrated trends of better outcomes than QSNYL alone for the treatment of melasma.

2018 Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology

22. Salicylic acid peeling combined with vitamin C mesotherapy versus salicylic acid peeling alone in the treatment of mixed type melasma: A comparative study. (PubMed)

Salicylic acid peeling combined with vitamin C mesotherapy versus salicylic acid peeling alone in the treatment of mixed type melasma: A comparative study. Melasma is a distressing condition for both dermatologists and patients. We evaluated the effectiveness of salicylic acid (SA) peel and vitamin C mesotherapy in the treatment of melasma.Fifty female patients were divided into two groups. All patients were treated with 30% SA peel every two weeks for two months. In addition, after SA peeling (...) Group A was intradermally administered 10 vitamin C on the melasma lesion at 1-cm intervals. All patients were followed up for 6 months, during which the recurrence rates were evaluated. Digital photographs of the melasma site were taken and patients' Melasma Area and Severity Index (MASI) scores were assessed. After the treatment, the patients were asked to complete the melasma quality of life questionnaire (MelasQoL) to evaluate their satisfaction with the treatment. All the adverse effects were

2018 Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology

23. Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a shor (PubMed)

Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a shor Melasma's high prevalence and profound psychological impact on patients necessitate efficacious, economical, and safe therapeutic interventions. Adjunctive therapies such as tranexamic acid (TA) can enhance the therapeutic effect of standard (...) treatments like hydroquinone 4% cream (HQ).To conduct an assessor- and analyst-blinded, parallel, superiority, randomized controlled trial to compare the clinical efficacy and safety of oral TA plus HQ vs. HQ alone in melasma treatment.A total of 100 eligible patients with symmetric facial melasma were assigned to the intervention (250 mg thrice daily oral TA plus HQ 4% cream nightly) or the control group (HQ 4% cream only). Following 3 months of treatment, MASI (melasma area and severity index) score

2018 Journal of cosmetic dermatology

24. Evaluation of Therapeutic Efficacy and Safety of Tranexamic Acid Local Infiltration in Combination with Topical 4% Hydroquinone Cream Compared to Topical 4% Hydroquinone Cream Alone in Patients with Melasma: A Split-Face Study (Full text)

Evaluation of Therapeutic Efficacy and Safety of Tranexamic Acid Local Infiltration in Combination with Topical 4% Hydroquinone Cream Compared to Topical 4% Hydroquinone Cream Alone in Patients with Melasma: A Split-Face Study Melasma is an acquired pigmentary disorder characterized by hyperpigmented macules and/or patches affecting sun-exposed skin. Tranexamic acid (TA) can reduce melanin content of epidermis. Thus, we conducted this study to evaluate the efficacy and safety of tranexamic acid (...) local infiltration in combination with topical 4% hydroquinone cream compared to topical 4% hydroquinone cream alone in patients with melasma.This study was a prospective assessor- and analyst-blind, randomized split-face clinical trial which was performed on patients with bilateral malar epidermal melasma. A total of 55 patients were enrolled, and each side of their face was randomly allocated to either TA+HQ or HQ alone treatment. The MASI score was applied as an objective measurement to compare

2018 Dermatology research and practice PubMed

25. LaseMD System for the Treatment of Melasma

LaseMD System for the Treatment of Melasma LaseMD System for the Treatment of Melasma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. LaseMD System for the Treatment of Melasma The safety and scientific (...) will evaluate the clinical outcomes associated with use of the LaseMD Laser System for the treatment of melasma. Condition or disease Intervention/treatment Phase Melasma Device: LaseMD System Not Applicable Detailed Description: This clinical trial is a designed as a prospective, multi-site, non-randomized study of 20 subjects. Subjects will receive up to 5 study treatments completed 21 days apart. Phone follow-up will occur at Day 3 following each treatment for the assessment of adverse events

2018 Clinical Trials

26. Oral Tranexamic Acid for the Treatment of Melasma: A Review. (PubMed)

Oral Tranexamic Acid for the Treatment of Melasma: A Review. Melasma is a common acquired disorder of hyperpigmentation that commonly affects those with skin of color. Tranexamic acid (TXA) is a novel treatment for melasma that has a multimodal mechanism of action.To provide a comprehensive review of the literature regarding the evidence on the mode of action, safety profile, and efficacy of TXA in the treatment of melasma.The literature was searched for publications on TXA in the treatment (...) of melasma using MEDLINE, Scopus, and Google Scholar.Oral TXA has clearly demonstrated the efficacy for melasma in Asian skin, even in low doses (e.g., 500 mg daily) over short periods (8-12 weeks). It is also a safe therapeutic option, which is easy to administer with few and mild side effects. Studies have shown that TXA does not increase the thromboembolic risk, although patients should be screened carefully for contraindications and risk factors prior to commencement of the therapy.Oral TXA is a safe

2018 Dermatologic Surgery

27. Oral Tranexamic Acid and Laser for Treatment of Melasma

Oral Tranexamic Acid and Laser for Treatment of Melasma Oral Tranexamic Acid and Laser for Treatment of Melasma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Oral Tranexamic Acid and Laser for Treatment (...) of Melasma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03686787 Recruitment Status : Recruiting First Posted : September 27, 2018 Last Update Posted : September 27, 2018 See Sponsor: Laser and Skin Surgery Center of New

2018 Clinical Trials

28. The Safety and Efficacy of Treatment With a 1,927-nm Diode Laser With and Without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types. (PubMed)

The Safety and Efficacy of Treatment With a 1,927-nm Diode Laser With and Without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types. The nonablative, fractional, 1,927-nm diode laser is theoretically a safe and effective treatment for hyperpigmentation and melasma in darker skin and may potentiate topical cosmeceutical delivery.To evaluate the use of a nonablative, fractional, 1,927-nm diode laser with and without topical 2% hydroquinone (HQ) cream for moderate

2018 Dermatologic Surgery

29. Pulsed Dye Laser versus Intense Pulsed Light in Melasma: A Split- Face Comparative Study. (PubMed)

Pulsed Dye Laser versus Intense Pulsed Light in Melasma: A Split- Face Comparative Study. Recent reports suggest that melasma may have a vascular component. Vascular targeting lasers and light treatment can be a therapeutic option that will provide benefits to the patients.To compare the efficacy and tolerability of pulsed dye laser (PDL) and intense pulsed light in treatment of melasma.Twenty-eight Egyptian female patients with melasma were treated with PDL on the right hemiface (Group (...) A) and with the intense pulsed light on the left hemiface (Group B). Clinical assessment was performed according to the hemifacial modified Melasma Area and Severity Index score (mMASI). Tissue biopsies were taken from patients for immunohistochemical staining with vascular endothelial growth factor (VEGF) antibody.The hemifacial mMASI score was significantly reduced after treatment in studied groups with no statistically significant difference. Intense pulsed light (IPL) group showed higher efficacy of treatment

2018 Journal of Dermatological Treatment

30. Estrogen associated with UVB irradiation recapitulates the specific melanosome distribution observed in Caucasoid Melasma. (PubMed)

Estrogen associated with UVB irradiation recapitulates the specific melanosome distribution observed in Caucasoid Melasma. 30478899 2019 01 01 1365-2133 2018 Nov 26 The British journal of dermatology Br. J. Dermatol. Oestrogen associated with ultraviolet B irradiation recapitulates the specific melanosome distribution observed in caucasoid melasma. 10.1111/bjd.17453 Gauthier Y Y Pigmentary Disorders Outpatient Clinic, National Reference Center for Rare Skin Disorders, Saint André, Hospital

2018 British Journal of Dermatology

31. Fractional erbium-doped yttrium aluminum garnet laser-assisted drug delivery of hydroquinone in the treatment of melasma (Full text)

Fractional erbium-doped yttrium aluminum garnet laser-assisted drug delivery of hydroquinone in the treatment of melasma Melasma is a difficult-to-treat hyperpigmentary disorder. Ablative fractional laser (AFL)-assisted delivery of topically applied drugs to varied targets in the skin has been an area of ongoing study and research.The objective of this study was to evaluate the efficacy and safety of fractional erbium-doped yttrium aluminum garnet (Er:YAG) laser as an assisted drug delivery (...) for enhancing topical hydroquinone (HQ) permeation into the skin of melasma patients.Thirty female patients with bilateral melasma were randomly treated in a split-face controlled manner with a fractional Er:YAG laser followed by 4% HQ cream on one side and 4% HQ cream alone on the other side. All patients received six laser sessions with a 2-week interval. The efficacy of treatments was determined through photographs, dermoscopic photomicrographs and Melasma Area Severity Index (MASI) score, all performed

2018 Clinical, cosmetic and investigational dermatology PubMed

32. Oral Tranexamic Acid and Topical Hydroquinone in the Treatment of Melasma

Oral Tranexamic Acid and Topical Hydroquinone in the Treatment of Melasma Oral Tranexamic Acid and Topical Hydroquinone in the Treatment of Melasma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Oral (...) Tranexamic Acid and Topical Hydroquinone in the Treatment of Melasma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03751163 Recruitment Status : Completed First Posted : November 22, 2018 Last Update Posted : November 26, 2018 Sponsor: Fakultas Kedokteran Universitas Indonesia Information provided

2018 Clinical Trials

33. Dual Effect of Photobiomodulation on Melasma: Downregulation of Hyperpigmentation and Enhanced Solar Resistance—A Pilot Study (Full text)

Dual Effect of Photobiomodulation on Melasma: Downregulation of Hyperpigmentation and Enhanced Solar Resistance—A Pilot Study Overview. Melasma is a resistant, sun-induced facial hyperpigmentation capable of remaining present for decades with ensuing psychological distress. Treatment is difficult and focuses on an array of measures to reduce skin hyperpigmentation resulting from triggered hyperactive melanocytes. The pathogenesis of melanoma is not clearly understood but it has been reported (...) that some growth factors and specific cell-signaling pathways are involved. Objective. The objective of the current study was to evaluate the use of pulsed photobiomodulation to modulate melasma via the regulation of gene expression pertaining to skin pigmentation. Methods. We evaluated a two-step approach via a spilt-face pilot study involving seven patients with bilateral dermal melasma who had formerly undergone unsuccessful treatments. During treatment, the initial mobilization phase

2018 The Journal of clinical and aesthetic dermatology PubMed

34. Melasma in Men: A Review of Clinical, Etiological, and Management Issues (Full text)

Melasma in Men: A Review of Clinical, Etiological, and Management Issues Melasma is a common skin condition that affects both men and women. However, it is more commonly seen in women and dark-skinned individuals, such as in Hispanics, Asians, and African Americans who live in areas with intense ultraviolet radiation. Melasma is less common in men, but it negatively affects the quality of life in men as much as it does in women. While melasma has been studied in detail in women, however (...) , there is a paucity of studies on the clinico- etiopathology and therapeutics of melasma in men. This article reviews and discusses important clinical, etiological, and treatment aspects of melasma in men. The authors recommend that clinicians educate their patients on the causes, prevention and treatment methods, and recurrence rates of melasma. The authors also recommend that clinicians take into careful consideration each patient's preferences and expectations when creating treatment regimens, as these might

2018 The Journal of clinical and aesthetic dermatology PubMed

35. Evaluation Instruments for Quality of Life Related to Melasma: An Integrative Review (Full text)

Evaluation Instruments for Quality of Life Related to Melasma: An Integrative Review The aim of this study was to analyze scientific production concerning the validation and cultural adaptation of quality of life evaluation instruments for patients with melasma and to offer a critical reflection on these methods. A literature review was performed based on a search of the Web of Science, Bireme, PubMed, Elsevier Scopus, and Google Scholar databases. All published articles from indexed (...) periodicals in these electronic databases up to December 2015 were included. Eight articles were identified, of which only one (12.5%) referred to the development and validation of a specific instrument for evaluation of the quality of life of melasma patients. An additional six articles (75%) referred to transcultural adjustment and validation of the same instrument in other languages, and another (12.5%) article reported the development of a generic instrument for evaluation of quality of life

2018 Clinics PubMed

36. Identification of Biomarkers and Characterization of Melasma

Identification of Biomarkers and Characterization of Melasma Identification of Biomarkers and Characterization of Melasma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Identification of Biomarkers (...) and Characterization of Melasma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03618277 Recruitment Status : Not yet recruiting First Posted : August 7, 2018 Last Update Posted : August 7, 2018 See Sponsor: Pierre Fabre Dermo

2018 Clinical Trials

37. Microneedle and Trichloroaceticacid in Treatment of Melasma

Microneedle and Trichloroaceticacid in Treatment of Melasma Microneedle and Trichloroaceticacid in Treatment of Melasma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Microneedle and Trichloroaceticacid (...) in Treatment of Melasma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03472235 Recruitment Status : Not yet recruiting First Posted : March 21, 2018 Last Update Posted : March 21, 2018 See Sponsor: Assiut University

2018 Clinical Trials

38. USE THE SYSTEMIC METFORMIN IN MELASMA

USE THE SYSTEMIC METFORMIN IN MELASMA USE THE SYSTEMIC METFORMIN IN MELASMA - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. USE THE SYSTEMIC METFORMIN IN MELASMA The safety and scientific validity (...) University Study Details Study Description Go to Brief Summary: Melasma is a chronic and relapsing acquired dyschromia due to an increased epidermal-melanin unit activity that affects sun-exposed areas mainly in women throughout the reproductive years. It is more common in women, accounting for 90% of all cases.The majority of patients are in third and fourth decades of their life. There are several risk factors that influence its appearance including genetic predisposition,exposure to heat and UV

2018 Clinical Trials

39. DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide.

DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide. DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03392623 Recruitment Status : Completed First Posted : January 8, 2018 Last Update Posted : January 9, 2018 Sponsor: Universidad

2018 Clinical Trials

40. Oral and Topical Tranexamic Acid for the Treatment of Melasma

Oral and Topical Tranexamic Acid for the Treatment of Melasma Oral and Topical Tranexamic Acid for the Treatment of Melasma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Oral and Topical Tranexamic Acid (...) for the Treatment of Melasma (TRANEXAMICO) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03585179 Recruitment Status : Not yet recruiting First Posted : July 12, 2018 Last Update Posted : July 16, 2018 See Sponsor: Centro

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>